SOURCE: Paragon Financial Limited

Paragon Financial Limited

April 19, 2012 08:20 ET

Patient Protection and Affordable Care Act Will Affect Medical Devices Industry Revenues in 2013

The Paragon Report Provides Stock Research on ICU Medical, Inc. and Boston Scientific Corp.

NEW YORK, NY--(Marketwire - Apr 19, 2012) - The aging U.S. population has been one of the driving factors for demand in the Medical Device Industry, as health issues that require medical devices are more common with the elderly. The nation's population of those 65 and older will double between 2000 and 2030, according to the federal Administration on Aging. Despite rapidly growing demand, revenues for the Industry are expected to take a major blow in the coming years. The Paragon Report examines investing opportunities in the Medical Devices Industry and provides equity research on ICU Medical, Inc. (NASDAQ: ICUI) and Boston Scientific Corporation (NYSE: BSX).

Access to full reports can be found at:

www.ParagonReport.com/ICUI

www.ParagonReport.com/BSX

The Patient Protection and Affordable Care Act (PPACA) will place a new 2.3 percent tax on the sales of medical devices in the U.S. starting in 2013. The device excise tax is charged on revenues of the devices not profits. Add this on top of existing federal, state, and local taxes companies in 2013 are looking to pay approximately 50 percent for every dollar earned in 2013. As a result we are already seeing companies downsizing their workforce, and eliminating investment in new facilities in the U.S.

Paragon Report releases regular market updates on the Medical Devices Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, announced results for the first quarter ended March 31, 2012. First quarter of 2012 revenue increased 5.7% to $75.5 million, compared to $71.5 million in the same period last year. Net income for the first quarter of 2012 was $7.6 million, or $0.53 per diluted share, as compared to net income of $8.1 million, or $0.57 per diluted share, for the first quarter of 2011.

Boston Scientific Corporation announced it will webcast its first-quarter 2012 financial results conference call on Thursday, April 19, at 8:00 a.m. Eastern Time. The call will be hosted by Hank Kucheman, chief executive officer, and Jeff Capello, executive vice president and chief financial officer.

Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
www.ParagonReport.com/disclaimer